The Peptide NewsroomPeptide research, industry and supply-chain headlines

GLP-1 Drugs Linked to Lower Pseudarthrosis Odds After Neck Fusion, But Other Outcomes Unclear

Photograph: Doctor Patient
Photo: "Doctor Patient" by Direct Media is marked with CC0 1.0. Source: https://stocksnap.io/photo/doctor-patient-8YUWCVJVHH

A systematic review and meta-analysis published in the European Spine Journal reports that perioperative use of glucagon-like peptide-1 receptor agonists was associated with lower odds of failed fusion after anterior cervical discectomy and fusion. Evidence on every other complication the authors looked at came back inconsistent.

GLP-1 receptor agonists are the drug class prescribed for type 2 diabetes and obesity, and the authors note their metabolic, anti-inflammatory and osteogenic effects raise questions about how they interact with spinal fusion. Anterior cervical discectomy and fusion, or ACDF, is a common neck operation in which a damaged disc is removed and the adjacent vertebrae are fused. Pseudarthrosis is the term for that fusion failing to knit.

Key results

The review pooled eight retrospective cohort studies covering 311,402 ACDF patients, of whom 8,182 were GLP-1RA users matched to non-users. Random-effects meta-analysis found significantly lower odds of pseudarthrosis among the GLP-1RA group at 6 months (OR 0.60, 95% CI 0.52 to 0.71), 12 months (OR 0.62, 95% CI 0.53 to 0.73), and 24 months (OR 0.67, 95% CI 0.57 to 0.79).

Heterogeneity across those three time points was low to moderate, which is worth noting in a pooled analysis of retrospective data. The consistency of the effect across all three intervals is the most interesting thing in the paper.

Where the signal stops

For reoperation, dysphagia, deep vein thrombosis and readmission, the authors describe the findings as heterogeneous and inconsistent across studies. That is not a negative result, it is an absence of one, and the review does not attempt to paper over it.

This is a question the spine literature had not addressed directly before. The authors say no systematic review had previously looked specifically at GLP-1RA exposure in ACDF, which makes even an inconclusive answer on secondary outcomes useful.

Limitations

Every included study was retrospective and observational, and the authors classify the work as Level III evidence. Association is not causation here, and matched cohorts cannot rule out that patients prescribed these drugs differ from those who are not in ways the data does not capture.

The authors conclude that prospective studies are required to further clarify the impact of GLP-1RA use on ACDF outcomes.

Bottom line

Perioperative GLP-1RA use was associated with lower odds of pseudarthrosis across three follow-up windows in a large pooled sample. Everything else about how these drugs interact with cervical fusion surgery remains unsettled.

Source: European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

GLP-1 Drugs Linked to Rare Sudden Vision Loss, But Absolute Risk Stays Low

A Rutgers-led study published in Annals of Internal Medicine links GLP-1 drugs including Ozempic and Wegovy to a modest increase in ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The lead author put the increase at roughly three to four additional cases per 10,000 patients over 18 months, and says the data does not establish causation.

Telangana Regulator Warns Online Peptide Buyers Risk Contamination, Serious Reactions and Death

Telangana's drug regulator TG SAFE has warned against buying or self-administering unapproved weight-loss drugs and experimental peptides sold on Telegram and other online platforms, naming BPC-157, GHK-Cu, retatrutide and tesamorelin. The advisory says such products may be contaminated, mislabelled or untested for sterility, and directs doctors not to prescribe them.

Gray Market Peptide Users Report Months of Side Effects, and the Research Is Thin

KFF Health News, written up by Futurism, reports on users of research-grade BPC-157 who describe fatigue, spasms and migraines lasting months after a few days of use. A former FDA official quoted in the piece says robust human studies on these compounds remain rare.